T&G Business @ Noon | MarketWatch | Business Columnists | On the Job
 
 
Search:
 

ChromaDex® Announces Financial Results for the Year Ended 2011

 

IRVINE, Calif., March 15, 2012 /PRNewswire/ -- ChromaDex Corporation (OTCBB: CDXC) an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries, today announced financial results for the fiscal year ended December 31, 2011. ChromaDex announced total revenues, prepared in accordance with United States Generally Accepted Accounting Principles (GAAP) of approximately $8.1 million and a net loss attributable to common stockholders of $0.12 per share for the fiscal year ended December 31, 2011. As of December 31, 2011, cash, cash equivalents and marketable securities totaled over $420,000. Subsequent to the fiscal year ended December 31, 2011, ChromaDex raised capital of approximately $10.1 million in net proceeds through the sale of its common stock.

(Logo:  http://photos.prnewswire.com/prnh/20110830/LA59283LOGO)

"Going into 2012, we are now poised to leverage our product and service offerings related to BluScience™, pTeroPure® and other novel ingredients. Our goal is to build ChromaDex into a leader in the natural products industry," said Jeffrey Himmel, CEO of ChromaDex.

"2011 was truly a landmark year for ChromaDex as the company launched its new dietary supplement product line, BluScience, into the market. Initial distribution of our BluScience products was achieved at a major drug chain and health food store as well as an online retailer. This was the first step in the BluScience national mass-market roll out plan," said Debra Heim, COO and President of the Consumer Products Division of ChromaDex.

Additional Financial Results & Notes

ChromaDex recorded revenue of $8,112,610 during the year of 2011 as compared to $7,566,370 in 2010, representing year on year growth of 7 percent. The net loss attributable to common stockholders for the fiscal year ended December 31, 2011, was $7,894,984 as compared to a net loss of $2,051,676 in 2010. The net loss in the year of 2011 was largely impacted by an increase in non-cash, share-based compensation expense related to the stock options that were granted following the May 20, 2010 private placement and other non-cash compensation. The effect of this increase, which is a "non-GAAP measure," decreased the net loss for the year of 2011 by $2,969,150 and decreased the loss per share for the year of 2011 by $0.04.

About ChromaDex®:

ChromaDex, Inc., a wholly owned and operated subsidiary of ChromaDex, is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. ChromaDex, Inc. has an expanding pipeline of new ingredients, including its pTeroPure® (http://www.pteropure.com) pterostilbene for which it has worldwide, exclusive patent pending rights. ChromaDex recently launched its BluScience™ (http://www.bluscience.com) line of dietary supplements. Capitalizing on the diverse potential applications of the product, ChromaDex is also developing pTeroPure for the pharmaceutical markets, among others. pTeroPure is currently being studied in a human clinical trial at the University of Mississippi.

For more information about pTeroPure visit www.pteropure.com or call 949-600-9694.

Forward-Looking Statements:

Any statements that are not historical facts contained in this release are "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in ChromaDex's filings with the Securities and Exchange Commission, and risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and ChromaDex does not undertake any obligation to update forward-looking statements. ChromaDex intends that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

ChromaDex Investor Contact:
Liviakis Financial Communications, Inc.
John M. Liviakis, President
415-389-4670
John@Liviakis.com

Institutions and Analysts Contact:
The Del Mar Consulting Group, Inc.
Robert B. Prag, President
858-794-9500
bprag@delmarconsulting.com

ChromaDex/BluScience Contact:
Jeffrey Himmel, CEO
949-419-0288
jsh@chromadex.com

ChromaDex Corporation and Subsidiaries






Consolidated Statements of Operations



Years Ended December 31, 2011 and January 1, 2011







2011

2010




Sales

$         8,112,610  

$         7,566,370  

Cost of sales

           5,640,791  

           4,621,525  




Gross profit

           2,471,819  

           2,944,845  




Operating expenses:



Sales and marketing

           2,539,252  

           1,085,510  

General and administrative

           7,796,806  

           3,876,488  

Operating expenses

         10,336,058  

           4,961,998  




Operating loss

         (7,864,239)  

         (2,017,153)  




Nonoperating income (expenses):



Interest income

                  1,397  

                  1,545  

Interest expense

              (32,142)  

              (36,068)  

Nonoperating expenses

              (30,745)  

              (34,523)  




Net loss

$       (7,894,984)  

$       (2,051,676)  







Basic and Diluted loss per common share

$                (0.12)  

$                (0.04)  







Basic and Diluted weighted average common shares outstanding

         68,306,812  

         48,251,930  




Quantitative reconciliation of the differences between the non-GAAP measure and the associated comparable GAAP measure














Consolidated Statements of Operations (US GAAP)



Effects of Non-cash Charges associated with




Consolidated Statements of Operations








Share-based Compensation Expense




Excluding Share-based Compensation (Non-GAAP Presentation)




Years Ended December 31, 2011 and January 1, 2011



Years Ended December 31, 2011 and January 1, 2011




Years Ended December 31, 2011 and January 1, 2011                       

















2011

2010



2011

2010



2011

2010














Sales

$  8,112,610

$  7,566,370


Sales

$                 -

$                 -


Sales

$  8,112,610

$  7,566,370


Cost of sales

5,640,791

4,621,525


Cost of sales

-

-


Cost of sales

5,640,791

4,621,525














Gross profit

2,471,819

2,944,845


Gross profit

-

-


Gross profit

2,471,819

2,944,845














Operating expenses:




Operating expenses:




Operating expenses:




Sales and marketing

2,539,252

1,085,510


Sales and marketing

-

-


Sales and marketing

2,539,252

1,085,510


General and administrative

7,796,806

3,876,488


General and administrative

(2,969,150)

(1,262,071)


General and administrative

4,827,656

2,614,417


Operating expenses

10,336,058

4,961,998


Operating expenses

(2,969,150)

(1,262,071)


Operating expenses

7,366,908

3,699,927














Operating loss

(7,864,239)

(2,017,153)


Operating income

2,969,150

1,262,071


Operating loss

(4,895,089)

(755,082)














Nonoperating income (expenses):




Nonoperating income:




Nonoperating income (expenses):




Interest income

1,397

1,545


Interest income

-

-


Interest income

1,397

1,545


Interest expense

(32,142)

(36,068)


Interest expense

-

-


Interest expense

(32,142)

(36,068)


Nonoperating expense

(30,745)

(34,523)


Nonoperating income

-

-


Nonoperating expense

(30,745)

(34,523)














Net loss

$(7,894,984)

$(2,051,676)


Net income

$  2,969,150

$  1,262,071


Net loss

$(4,925,834)

$   (789,605)














Basic and Diluted loss per common share

$         (0.12)

$         (0.04)


Basic and Diluted income per common share

$           0.04

$           0.03


Basic and Diluted loss per common share

$         (0.07)

$         (0.02)














Basic and Diluted weighted




Basic and Diluted weighted




Basic and Diluted weighted




 average common shares outstanding

68,306,812

48,251,930


 average common shares outstanding

68,306,812

48,251,930


 average common shares outstanding

68,306,812

48,251,930



SOURCE ChromaDex

Back to top
 DEPARTMENTS
Sign up here to receive T&G Business @ Noon
 THE MARKET
 SPECIAL COVERAGE
On the Job
Every Monday
     
T&G Classifieds
View Legal Notices
Place a classified ad

Home Delivery
Subscribe
Renew
Vacation stops
Billing changes
Help page

Newsletters
Click here to sign up for:
Reader Recap
Breaking News Alert
Headline news
Parking Ban Alert
Business@Noon



News | Entertainment | RSS | Personals | Corrections | Weather | Company Store | Privacy Policy| Submissions Policy| Contact us

© Worcester Telegram & Gazette Corp.

Order the Telegram & Gazette, delivered daily to your home or office!